Infervision vs Qure AI (2026)
Two imaging AI companies that built for scale in their home markets before the US. Infervision spans lung nodule detection and chest interpretation, with US operations alongside its origin market, which gives an American buyer a closer support relationship, and coverage across modalities. Qure sells chest X-ray, head CT, chest CT and musculoskeletal products in more than 105 countries by its own count. Its US clearances include qXR-Detect, a concurrent reading aid for six categories of chest X-ray findings with a Predetermined Change Control Plan, and qXR-LN, a second reader for lung nodules. A US health system that wants chest coverage with local support looks at Infervision. A buyer that wants chest X-ray detection with a cleared update plan, or tuberculosis screening, looks at Qure.
- A suite spanning lung nodule detection and chest interpretation, with US operations alongside its origin market.
- For a health system that wants chest coverage from a vendor with an American presence, the support relationship is closer.
- Coverage across modalities rather than radiography alone.
- A cleared change plan for qXR-Detect, setting out how the model can be updated and how users are told.
- Tuberculosis screening evidence from independent studies in several countries and a 2025 systematic review.
- A stated privacy position: its cloud path receives only images stripped of identifiers, and it states ISO 27001 certification as its own.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Infervision and Qure AI are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Infervision | Qure AI |
|---|---|---|
| Primary category | Radiology & Imaging AI | Radiology & Imaging AI |
| Founded | 2015 | 2016 |
| Headquarters | Beijing, China | Mumbai, India |
| Website | global.infervision.com | qure.ai |
Side by Side
Select any grade to read the note behind it.
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Beijing based imaging AI company whose InferRead line detects findings on CT and radiographs (lung nodules on chest CT, chest abnormalities on radiographs, coronary stenosis on CTA, hemorrhage on head CT, chest fractures and pneumonia), alongside the InferOperate suite of 3D reconstructions for thoracic, liver and urologic surgical planning, InferCare for patient follow up and RECIST tumor assessment, and the InferScholar research and InferMatrix application platforms.
Source: AI Health Index, August 2026
Qure.ai, founded in 2016 in Mumbai with a US entity in New York, sells radiology AI in more than 105 countries through more than 5,500 sites by its own count. Its products are qXR for chest X-ray (detection, reporting, lung nodules and tuberculosis screening), qER for head CT in stroke and trauma, qCT for chest CT nodules and lung cancer, qMSK for musculoskeletal X-ray, and heart failure detection.
Source: AI Health Index, August 2026
Questions buyers ask
How do Infervision and Qure AI work with the EHR?
For Infervision, the InferRead Lung CT.AI 510(k) summary (K240554) lists DICOM image input and reporting of results, with detection marks delivered as an overlay on the original CT. The product is reported in use at SimonMed, a US outpatient imaging provider, and in tuberculosis screening programs.
With Qure AI, the qXR page promises zero integration effort and deployment on cloud or on premise, the company says its software works with new and old X-ray systems, and the qXR-Detect summary describes results returned to radiology software or the X-ray console; qXR-LN is cleared for use with any DICOM viewer or PACS. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified August 4, 2026. No vendor pays for placement.
How are Infervision and Qure AI priced and sold?
In Infervision's case, the company is reported to offer several pricing options rather than a single model, and its tuberculosis screening deployments were procured through international agencies by public tender, where the price is disclosed to the purchaser rather than published. The products are sold directly and through public procurement, but what drives the cost is not stated.
For Qure AI, the portfolio makes the gap matter. Qure sells chest X-ray, head and chest CT and musculoskeletal products under ten US clearances, plus tuberculosis care cascades and the Aira care delivery platform, and nothing says whether indications are licensed singly, bundled by modality or sold as a platform. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified August 4, 2026. No vendor pays for placement.
How do Infervision and Qure AI handle patient data?
With Infervision, the InferRead Lung CT.AI 510(k) summary (K240554) says the software can run in the healthcare facility or on a cloud platform, and that cybersecurity and vulnerability analyses found it conforms to the cybersecurity requirements, a general assurance about the product.
Qure's Security and Regulatory page says data is de-identified before it leaves a covered entity's premises for cloud processing, and that on-premise installations may process identifiable images only on servers the customer owns and operates. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified August 4, 2026. No vendor pays for placement.
Which settings and specialties do Infervision and Qure AI cover?
For Infervision, the lung nodule product is cleared for asymptomatic people aged 55 and over with nodules of 4 mm and larger on chest CT, and its 2025 summary tests its follow up functions on lung cancer screening scans; hemorrhage triage on head CT, surgical planning for thoracic, liver and urologic surgery, and RECIST tumor assessment carry their own US clearances.
Qure covers chest X-ray, head and chest CT and musculoskeletal X-ray, sold to hospitals, imaging centers, teleradiology services, immigration screening and public health programs in more than 105 countries. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified August 4, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
Infervision's record has not yet been reviewed on this site, so its side of this page rests on the build record; ask it for security attestations and business associate terms. Do not compare on findings counts, which each counts differently.
Qure's US summaries report area under the curve or sensitivity without the number of scans tested, and it markets sorting out unremarkable chest X-rays without saying who reads the studies set aside. Prevalence in your own population decides the false positive burden more than published sensitivity.